Meeting
2019 ASCO Annual Meeting
Phase II trial of nivolumab with chemotherapy as neoadjuvant treatment in inflammatory breast cancer.
Authors
Maryann J. Kwa
New York University Cancer Institute, New York, NY
Maryann J. Kwa , Nancy Tray , Francisco J. Esteva , Yelena Novik , James L. Speyer , Ruth Oratz , Marleen Iva Meyers , Franco Muggia , Victor Ty , Andrea Troxel , Robert Schneider , Sylvia Adams
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Neoadjuvant Therapy
Clinical Trial Registration Number
NCT03742986
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS604)
DOI
10.1200/JCO.2019.37.15_suppl.TPS604
Abstract #
TPS604
Poster Bd #
92a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer.
First Author: Hatem Hussein Soliman
Poster
2020 ASCO Virtual Scientific Program
A phase III trial of nivolumab with neoadjuvant chemotherapy and adjuvant endocrine therapy in ER+/HER2- primary breast cancer: CheckMate 7FL.
First Author: Sherene Loi
Poster
2023 ASCO Annual Meeting
Neoadjuvant single-dose trilaciclib prior to combination chemotherapy in patients with early triple-negative breast cancer: Safety, efficacy, and immune correlate data from a phase 2 study.
First Author: Jeremy Meyer Force
Poster
2021 ASCO Annual Meeting
The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).
First Author: Nour Abuhadra